TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04942184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory strategies in Arm 1
Description: Memory strategies will consist of daily at-home exercises lasting between 20 minutes to 1 hour depending on the memory tasks assigned to each participant. At the start of week 1 participants will be taught the memory strategies to use while completing the daily memory tasks. In week 1 and 2, subjects will be reminded daily to use the memory strategies. At the start of week 3, subjects will be advised to use the memory strategies however they will not be given daily reminders.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalogram (EEG) headset in Arm 1
Description: A cap that measures brain activity using a 16-sensor wireless dry (no gel applied) EEG device designed by BrainWaveBank Ltd., that uses Bluetooth technology to securely transmit EEG signals to an Android tablet. The cap will be used during week 1,2,3 and 4.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tablet in Arm 1
Description: A computer tablet will be provided to each participant that will have daily reminders about the memory strategies during week 1 and 2, while no reminders will be present in week 3 and 4. The tablet software includes a user-friendly interface that provides feedback and instructions that help the participant properly wear the EEG headset. At the end of each session the tablet stores behavioral and EEG data on a secured server accessible by the research staff.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Memory strategies in Arm 2
Description: Memory strategies will consist of daily at home exercises lasting between 20 minutes to 1 hour depending on the memory tasks assigned to each participant. During weeks 1 and 2, participants will be completing the memory tasks without being instructed to use any specific strategy. At the end of week 2 subjects will be taught the memory strategies and during week 3 and 4, they will be reminded daily to use the memory strategies while completing the memory tasks.
Study: NCT06246864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Description: After the oral gastric tube is placed on the premature baby and fixed with a Hydrocolloid dressing, the fixed patch will be removed after 24 hours using a silicone-based spray remover.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypoallergenic Flexible
Description: After the oral gastric tube is placed on the premature baby and fixed with a hypoallergenic flexible patch, the fixed patch will be removed after 24 hours using a silicone-based spray remover.
Study: NCT05657249

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non-contrast focused MRI
Description: non-contrast liver MRI focusing on HCC surveillance in a short scan time.
Study: NCT05187897

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHV-NEO
Description: CHV-NEO is a two-way SMS platform that supports communication between mothers and community health volunteers between home visits. The platform engages mothers with SMS communication and brings timely information and support - asking critical questions at crucial times in order to assess the needs and health of newborns and assist in care seeking decisions. The CHV-NEO SMS intervention is integrated into the current digital community health toolkit (dCHT) to support CHV workflow.
Study: NCT04823286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality health platform during hemodialysis
Description: Subjects will play a virtual reality game specially adapted for subjects undertaking hemodialysis. The game will also aim at providing nutritional advice, and improving psychological wellbeing and cognitive function.
Study: NCT06485713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trifluridine/tipiracil combined with fufuquitinib
Description: trifluridine/tipiracil combined with fufuquitinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fufuquitinib
Description: fufuquitinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trifluridine/tipiracil
Description: Trifluridine/tipiracil
Study: NCT05542095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Compounded simvastatin that is suspended within a nasal saline irrigation will be utilized throughout this study. Participants will suspend the contents of the simvastatin capsules (0.1mg, 0.25 mg, 0.5 mg, and 1 mg) into the sinus rinse bottle containing nasal saline. All participants will receive an 8-ounce sinus rinse bottle and a 4-week supply of USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets. Participants will either need to purchase distilled water or boil tap water for five minutes for use with the saline irrigation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Compounded simvastatin that is suspended within a nasal saline irrigation will be utilized throughout this study. Participants will suspend the contents of the simvastatin capsules (0.1mg, 0.25 mg, 0.5 mg, and 1 mg) into the sinus rinse bottle containing nasal saline. All participants will receive an 8-ounce sinus rinse bottle and a 4-week supply of USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets. Participants will either need to purchase distilled water or boil tap water for five minutes for use with the saline irrigation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Compounded simvastatin that is suspended within a nasal saline irrigation will be utilized throughout this study. Participants will suspend the contents of the simvastatin capsules (0.1mg, 0.25 mg, 0.5 mg, and 1 mg) into the sinus rinse bottle containing nasal saline. All participants will receive an 8-ounce sinus rinse bottle and a 4-week supply of USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets. Participants will either need to purchase distilled water or boil tap water for five minutes for use with the saline irrigation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Compounded simvastatin that is suspended within a nasal saline irrigation will be utilized throughout this study. Participants will suspend the contents of the simvastatin capsules (0.1mg, 0.25 mg, 0.5 mg, and 1 mg) into the sinus rinse bottle containing nasal saline. All participants will receive an 8-ounce sinus rinse bottle and a 4-week supply of USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets. Participants will either need to purchase distilled water or boil tap water for five minutes for use with the saline irrigation.
Study: NCT04659304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allocetra-OTS
Description: Cell-based therapy comprised of allogeneic non-HLA matched peripheral blood mononuclear cells induced to an early apoptotic state.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allocetra-OTS
Description: Cell-based therapy comprised of allogeneic non-HLA matched peripheral blood mononuclear cells induced to an early apoptotic state.
Study: NCT04942184

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroencephalogram (EEG) headset in Arm 2
Description: A cap that measures brain activity using a 16-sensor wireless dry (no gel applied) EEG device designed by BrainWaveBank Ltd., that uses Bluetooth technology to securely transmit EEG signals to an Android tablet. The cap will be used during week 1,2,3 and 4.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tablet in Arm 2
Description: A computer tablet will be provided to each participant. During week 3 and 4, the tablet will present daily reminders to use memory strategies while completing the memory tasks. The tablet software includes a user-friendly interface that provides feedback and instructions that help the participant properly wear the EEG headset. At the end of each session the tablet stores behavioral and EEG data on a secured server accessible by the research staff.
Study: NCT05247437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Intensive Lifestyle Intervention
Description: The FitD consists of 8 digital lessons on how to improve dietary and exercise habits using self-monitoring, goal-setting, cognitive restructuring, and other behavioral and cognitive strategies. The FitD app offers a virtual coach that guides the participant to complete the treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital Self-Help Control Condition
Description: The digital self-help control condition consists of educational materials related to diet and exercise. The materials are open for access all at once. There is no guidance by a virtual coach or digital lessons.
Study: NCT06510166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Children's Fear and Anxiety normal nebulizer and mask+ distraction
Description: Children in group 2 will receive their inhaler treatment with a normal nebulizer and mask, while at the same time one of the distraction techniques of their choice (drawing a picture, reading a story or watching an age-appropriate cartoon) will be applied.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Children's Fear and Anxiety a toy nebulizer and a toy mask
Description: Children in Group 3 will receive their inhaler treatment using a toy nebulizer and a toy mask.
Study: NCT05267769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP707
Description: Preparation of Cannabis flowers (Cannabis flos)
Study: NCT04518293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
Description: Single pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg
Description: Signle pill
Study: NCT04887337

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic stabilization
Description: Early arthroscopic stabilization with Bankart repair

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation including a period of immobilization followed by physical therapy
Description: Rehabilitation including a period of immobilization followed by physical therapy
Study: NCT05335928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept plus
Description: Up to 4 study drug infusions at 10 mg/kg, IV~Drug: Standard of care Local standard of care per written policies or guidelines Other Name: SoC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Standard of care Local standard of care per written policies or guidelines Other Name: SoC
Study: NCT05873686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXP900
Description: NXP900 is an orally administered SRC/YES1 kinase inhibitor
Study: NCT06638463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Health Coach app
Description: My Health Coach is a self-directed mobile health intervention for adults with FASD. It is grounded in self-determination theory and integrates well-established behavior change strategies. It has a cloud-based infrastructure and uses a just-in-time adaptive intervention design and a simple and engaging chatbot interface. It provides adults just the right type and amount of support, when they are most receptive.
Study: NCT04659304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allocetra-OTS
Description: Cell-based therapy comprised of allogeneic non-HLA matched peripheral blood mononuclear cells induced to an early apoptotic state.
Study: NCT05403905

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non surgical treatment
Description: Conservative treatment is required to use a curved splint for 6 weeks to keep the feet on the ground, bathing and sleeping without loosening the utensils and taking no steroids during the period. Physical examination and magnetic resonance imaging were performed after 6 weeks. If laxity remained unsatisfactory, the outcome was recorded as failure and surgery was changed.
Study: NCT04839068

Intervention type: DEVICE
Intervention: covid 19 on pregnancy outcomes
Description: covid 19 on pregnancy outcomes and sex ratio at birth

Intervention type: DEVICE
Intervention: covid 19 on pregnancy outcomes
Description: covid 19 on pregnancy outcomes and sex ratio at birth
Study: NCT05403905

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical treatment
Description: The patient underwent knee arthroscopic anterior cruciate ligament surgery at the Institute of Sports Medicine of the Third Hospital of Peking University. The surgical methods were all anatomical single-bundle.
Study: NCT04518293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan 20 mg/amlodipine 2.5 mg .
Description: oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telmisartan 40 mg/amlodipine 5 mg
Description: oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan 20 mg/indapamide 1.25 mg
Description: oral tablet
Study: NCT05889299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS906 study drug
Description: OMS906 study drug dose repeat-dose 5mg/kg SC administration at 4-week intervals
Study: NCT05322291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobil Application
Description: The mobile application developed will be installed on the phones of hemodialysis patients
Study: NCT05555641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafamostat Mesylate
Description: ECMO patients were given continuous anticoagulation with nafamostat mesylate, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated Heparin
Description: ECMO patients were given continuous anticoagulation with unfractionated heparin, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
Study: NCT05414448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENDOCUFF
Description: ENDOCUFF mucousal exposure device will be used during withdrawal process of the colonoscopy.
Study: NCT04626687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: test DCB
Description: use paclitaxel coated coronary balloon catheters to treat SVD

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RESTORE DCB
Description: use paclitaxel coated coronary balloon catheters(RESTORE DCB) with NMPA approval indication for treating SVD
Study: NCT06549166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: VR and exercise
Description: Participants will perform a 20-minute exercise program consisting of neck joint mobility exercises, neck and scapulothoracic muscle strengthening exercises, and stretching exercises. Then, for the next 20 minutes, they will engage in active neck movements using the Oculus Quest2 headset with the Ocean Rift game.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: exercise
Description: The control group will perform a 40-minute same neck exercises.
Study: NCT04731298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emapalumab
Description: Emapalumab is a fully human immunoglobulin G1 (IgG1) anti-IFNγ monoclonal antibody that binds to and neutralizes IFNγ. Emapalumab binds to both soluble and receptor (IFNγR1)-bound forms of IFNγ.~Emapalumab is in development for treatment of primary and secondary HLH. The benefit expected from the targeted neutralization of IFNγ by emapalumab has been validated by the recent FDA approval of emapalumab for treatment of patients with pHLH who have refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. The safety profile has been assessed as acceptable.~Emapalumab will be administered by intravenous infusion over 1 to 2 hours, depending on the volume of the infusion. The first infusion must be performed within 12 hours after CXCL9 levels have been measured above defined threshold. Treatment will last until maximum dose 15 (up to 56 days) or until evidence of engraftment, whichever comes first.
Study: NCT05090163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PREP Plus
Description: Group based exercise in addition to PREP exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PREP
Description: Group based exercise
Study: NCT04409561

Intervention type: DEVICE
Intervention: Blood collection
Description: 9 mL K3-EDTA anticoagulated venous whole blood and 9 mL lithium heparin anticoagulated venous whole blood will be collected, processed in plasma and stored until the shipment to the sponsor for PSP measurement on the abioSCOPE device with IVD CAPSULE PSP kits
Study: NCT04518293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telmisartan 40 mg/indapamide 2.5 mg
Description: oral tablet
Study: NCT05808595

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AlphaWave® L-Theanine
Description: One capsule of AlphaWave® L-Theanine will be taken twice daily for 28 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule of Placebo will be taken twice daily for 28 days.
Study: NCT04558723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICD/CRT-D implantation
Description: ICD/CRT-D implantation (if indicated)
Study: NCT06008236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation and Breathing Exercises
Description: Progressive relaxation exercise is a method that provides relaxation in the whole body by voluntary, regular relaxation of large muscle groups in the human body. Exercise helps individuals to be able to feel the difference between tension in the muscles and relaxation, and to learn to relax on their own in case of tension. Deep breathing exercise supports the maximum ventilation of the lung by correct breathing using the diaphragm.
Study: NCT05403476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999049
Description: FE 999049 is administered as single daily subcutaneous injections of 12 μg for 6 months.
Study: NCT04518293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 2.5 mg/indapamide 1.25 mg
Description: oral tablet
Study: NCT05403476

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049 for 6 months.
Study: NCT04518293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine 5 mg/indapamide 2.5 mg
Description: oral tablet
Study: NCT06246214

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blue Light Therapy
Description: The BlueLT device is equipped with a narrow band short wavelength Light Emitting Diode (LED) - wavelength peak(λp) of \~470 nm (blue).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ControlLT
Description: The ControlLT (placebo) device is equipped with a dim long-wavelength enriched LED.
Study: NCT06489626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 4 milligram Tab
Description: 6-day 4 milligram methylprednisolone oral taper

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone injection
Description: 4 milligram intravenous dexamethasone will be administered intraoperatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone injection
Description: 4 milligram intravenous dexamethasone will be administered intraoperatively
Study: NCT06632249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice with the virtual reality game
Description: 4 weeks of practice with the virtual reality game, totalling 20 sessions, 5 supervised in the laboratory and 15 at home with remote monitoring.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Practice with the virtual reality game
Description: 4 weeks of practice with the virtual reality game, totalling 20 sessions, 5 supervised in the laboratory and 15 at home with remote monitoring.
Study: NCT06632587

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early cranioplasty
Description: Cranioplasty is the surgical procedure to restore the skull after a decompressive hemicraniectomy. The latter procedure is employed as a life-saving measure to relieve intracranial pressure in patients with acute cranial injuries. Early cranioplasty is defined as being performed within 8 weeks following the decompressive hemicraniectomy.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard-of-care cranioplasty
Description: Cranioplasty is the surgical procedure to restore the skull after a decompressive hemicraniectomy. The latter procedure is employed as a life-saving measure to relieve intracranial pressure in patients with acute cranial injuries. Standard-of-care cranioplasty is defined as being performed after 3 months following the decompressive hemicraniectomy.
Study: NCT06634121

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter mitral valve edge-to-edge repair (M-TEER)
Description: M-TEER is performed via a transfemoral venous approach. After puncture of the interatrial septum the mitral valve is repaired using either the PASCAL or MitraClip device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter mitral valve edge-to-edge repair (M-TEER)
Description: M-TEER is performed via a transfemoral venous approach. After puncture of the interatrial septum the mitral valve is repaired using either the PASCAL or MitraClip device.
Study: NCT05565599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Closure
Description: Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure System.
Study: NCT05906914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cladribine + homoharringtonine + cytarabine
Description: CHA Protocol: cladribine (5mg/m2, d1-3) + homoharringtonine (2mg/m2, d1-5) + cytarabine (100mg/m2 d1-7).
Study: NCT06634225

Intervention type: DIAGNOSTIC_TEST
Intervention: Usual care (as recommended by the Haute Authorité de Santé (HAS)) and medical device test
Description: Patients will receive the care they need, in line with HAS recommendations. They will be asked to perform two gait analysis tests on a three-dimensional platform, equipped with sensors (medical device).

Intervention type: DIAGNOSTIC_TEST
Intervention: Usual care (as recommended by the Haute Authorité de Santé (HAS)) and medical device test
Description: Patients will receive the care they need, in line with HAS recommendations. They will be asked to perform two gait analysis tests on a three-dimensional platform, equipped with sensors (medical device).